Premium
High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia
Author(s) -
Wu Lina,
Xia Miaoran,
Sun Xiaoping,
Han Xin,
Zu Youli,
Jabbour Elias J.,
You M. James,
Lin Pei,
Li Shaoying,
Xu Jie,
Han Haibo,
BuesoRamos Carlos E.,
Medeiros L. Jeffrey,
Qiu Xiaoyan,
Yin C. Cameron
Publication year - 2020
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13466
Subject(s) - immunoglobulin d , immunoglobulin e , antibody , immunology , bone marrow , immunoglobulin m , immunoglobulin g , immunoglobulin gene , myeloid , medicine , immunophenotyping , myeloid leukemia , immunoglobulin class switching , cd23 , immunoglobulin heavy chain , biology , b cell , flow cytometry
Objectives It has been believed that immunoglobulins can only be produced by B lymphocytes and plasma cells. We have previously reported that IgG can be expressed in myeloblasts from patients with acute myeloid leukemia (AML) and plays a role in the proliferation and apoptosis of leukemic cells. However, its clinical impact has not been assessed. Methods We assessed the expression of different classes of immunoglobulin in peripheral blood and bone marrow samples from 132 AML patients and correlated the levels of expression with clinicopathologic and molecular genetic features, as well as clinical outcome. Results We found that, in addition to IgG, all classes of immunoglobulin are expressed in myeloblasts, including IgG, IgM, IgA, IgD, IgE, Igκ, and Igλ. The levels of IgG expression (coupled with Igκ or Igλ) are higher than those of IgM, IgA, IgD, and IgE. Using receiver operating characteristic (ROC) curve analysis, we identified two distinct groups of AML patients with differential expression of immunoglobulin and different clinical outcomes. Conclusions High levels of immunoglobulin expression are associated with monocytic differentiation, multilineage dysplasia, TET2 and KRAS mutations, and poor overall survival. Assessment of immunoglobulin may serve as a useful marker for prognostic stratification and target therapy.